Aurobindo Pharma Ltd.‘s revenue in Q2FY23 fell 3% to ₹ 5,739 crores. Consolidated Profit came at ₹ 409 crores showcasing a 41% fall YoY over the corresponding period.
In this quarter’s press release, the reports suggested that the firm has observed a fall in profits due to a rise in expenses.